U.S. markets closed

IntelGenx Technologies Corp. (IGXT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2673-0.0027 (-1.00%)
At close: 3:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2700
Open0.2379
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.2379 - 0.2850
52 Week Range0.1200 - 0.6000
Volume273,579
Avg. Volume186,252
Market Cap29.473M
Beta (5Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-0.0810
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    IntelGenx Grants Stock Options

    SAINT-LAURENT, Quebec, Nov. 23, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTCQB:IGXT) announced today that the Company’s board of directors granted stock options to acquire a total of 1,365,000 common shares under the 2016 Stock Option Plan. Of the total stock options granted, 200,000 were granted to each of Horst G. Zerbe, Chief Executive Officer and Andre Godin, President and Chief Financial Officer. Furthermore, 100,000 stock options were granted to each of three officers of IntelGenx Corp., Nadine Paiement, Vice President Research and Development, Dana Matzen, Vice President Business and Corporate Development and Rodolphe Obeid, Vice President Operations. Also included in the total number of options granted are 665,000 granted to fourteen employees of IntelGenx Corp.The options have an exercise price of US$0.27 (CAD$0.35), vest over a period of two years at the rate of 25% every six months and expire on November 22, 2030.About IntelGenx:IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.IntelGenx’s superior film technologies, including VersaFilm® and VetaFilm™, as well as its transdermal development and manufacturing capabilities, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQB accepts responsibility for the adequacy or accuracy of this release.Contact: IntelGenx Technologies Corp. Ingrid Zerbe Corporate Secretary 514-331-7440 ingrid@intelgenx.com

  • GlobeNewswire

    IntelGenx Reports Third Quarter 2020 Financial Results

    SAINT LAURENT, Quebec, Nov. 12, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2020. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. 2020 Third Quarter Financial Summary: * Revenue was $510,000, compared to $61,000 in the 2019 third quarter * Adjusted EBITDA loss was ($1.2 million), compared to ($2.3 million) in Q3-2019Recent Developments: * Issued U.S. Patent 10,828,254 entitled “Oral film formulation for modulating absorption profile,” which covers a novel oral film dosage technology platform for modulating the in vivo absorption profile of a sublingually- or buccally-administered active ingredient. * Announced the publication of a study in the peer-reviewed International Journal of Clinical Pharmacy evaluating Montelukast’s effect on neurological aging. * Closed a private placement in two tranches, raising a total of $1.8 million principal amount of 8% convertible notes due October 15, 2024. * Signed a binding letter of intent (“LOI”) with Heritage Cannabis Holdings Corp. (CSE:CANN; OTCQX:HERTF) (“Heritage”) for the supply of filmstrip products containing CBD for the Canadian and Australian markets. * Entered into an amended and restated license agreement, granting Tetra Bio-Pharma (TSX:TBP; OTCQB:TBPMF) (“Tetra”) additional exclusive worldwide rights, including the right to manufacture, IntelGenx’s Adversa® mucoadhesive delivery technology. * Expanded its RIZAPORT® commercialization agreement with Exeltis Healthcare S.L. (“Exeltis”) to include the European Union. * Entered into a feasibility agreement with ATAI Life Sciences (“ATAI’) for the development of novel formulations of pharmaceutical-grade psychedelics. * Amended the exclusivity terms of its November 2018 license, development and supply agreement with Tilray, Inc. to allow for IntelGenx’s co-development and commercialization of CBD products with additional partners. * Entered into a feasibility agreement with Cybin Corp. for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin. “We began to see the results of our performance improvement program being reflected in our financial results this quarter,” said Dr. Horst G. Zerbe, CEO of IntelGenx. “We have also continued to execute on our business development strategy by granting Tetra additional exclusive worldwide rights to our Adversa® technology, and entering into a feasibility agreement and a LOI with ATAI and Heritage, respectively, related to our filmstrip technology. In addition, we added 26 European countries to our existing RIZAPORT® commercialization partnership with Exeltis, and are looking forward to their launch of the product in at least one major market early next year.”Financial Results:Total revenues for the three-month period ended September 30, 2020 amounted to $510,000, an increase of $449,000, or 736%, compared to $61,000 for the three-month period ended September 30, 2019. The increase is mainly attributable to a $308,000 and $141,000 increase in licensing agreement and research and development revenues, respectively.Operating costs and expenses were $1.9 million for the third quarter of 2020, versus $2.6 million for the corresponding three-month period of 2019. The decrease for the three-month period ended September 30, 2020 is mainly attributable to a $691,000 decrease in selling, general and administrative expenses.For the third quarter of 2020, the Company had an operating loss of $1.4 million, compared to an operating loss of $2.5 million for the comparable period of 2019.Net comprehensive loss for the three-month period ended September 30, 2020 was $1.6 million, or $0.01 per basic and diluted share, compared to net comprehensive loss of $2.9 million, or $0.03 per basic and diluted share, for the comparable period of 2019.As at September 30, 2020, the Company's cash and short-term investments totalled $1.5 million, which did not include gross proceeds of $1.8 million raised by the Company in its October 2020 convertible notes offering.Conference Call Details:IntelGenx will host a conference call to discuss these 2020 third quarter financial results today, Thursday, November 12, 2020, at 4:30 p.m. ET.Live Call: 1-800‑459‑5346 (Canada and the United States)  1-203‑518‑9544 (International) The call will be also be webcast live and archived for twelve months at www.intelgenx.com.About IntelGenxIntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.IntelGenx’s superior film technologies, including VersaFilm® and VetaFilm™, as well as its transdermal development and manufacturing capabilities, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.Forward Looking Statements:This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions, including, without limitation, anticipated commencement of commercial production of cannabis-infused VersaFilm® and how long operations can be funded based on current assets. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it will have on IntelGenx’s operations, the demand for its products, global supply chains and economic activity in general. IntelGenx assumes no obligation to update any such forward-looking statements.Each of the TSX Venture Exchange and OTCQB has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Source: IntelGenx Technologies Corp.For IntelGenx:Stephen Kilmer Investor Relations (514) 331-7440 ext 232 stephen@intelgenx.comOrAndre Godin, CPA, CA President and CFO IntelGenx Corp. (514) 331-7440 ext 203 andre@intelgenx.com

  • ACCESSWIRE

    IntelGenx Technologies Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 12, 2020 / IntelGenx Technologies Corp.